{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T04:04:02Z","timestamp":1777003442310,"version":"3.51.4"},"reference-count":33,"publisher":"Innovative Healthcare Institute","issue":"2","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>TLR9 agonists are immunomodulators that have been of interest for combined use with cancer immunotherapy. TLR9 agonists, such as lefitolimod (MGN1703), significantly increased Th1 response in preclinical models and have demonstrated efficacy in early clinical trials. This trial assessed the safety and preliminary efficacy of the combination of lefitolimod and ipilimumab in patients with advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-center, open-label, investigator-initiated phase I trial conducted at The University of Texas MD Anderson Cancer Center. Patients received leftolimod either subcutaneously (at escalating doses of 15\u2013120 mg) or intratumorally (at the maximum feasible dose) in combination with ipilimumab (3 mg\/kg). Paired biopsy samples were collected before the start of treatment and after two treatment cycles and analyzed by flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We enrolled a total of 28 patients in this study with a median age of 56 years (range 19\u201375) in the escalation cohort and 60 years (range 34 \u201392) in the expansion cohort. The median number of prior lines of therapy was 4 (range 0\u201312). Eleven patients had at least one treatment-related adverse event (TRAE). The most common TRAEs were skin rash (n = 4, 14%), fatigue (n = 3, 11%), and pruritis (n = 2, 7%). No grade 4 or 5 AEs occurred, and no patients required dose reduction or treatment discontinuation due to AEs. The maximum tolerated dose (MTD) was not reached in this study. Of 28 patients, 21 patients had response-evaluable disease. No patients had a complete or partial response; 8 and 13 patients had stable and progressive disease as the best response, respectively. Paired biopsy samples were obtained from five patients. Increases in intratumoral CD8 T-cell frequency, memory CD8 phenotype (CD45RO+), and proliferation (Ki67+) in four of five patients suggested that the combination of lefitolimod and ipilimumab led to proinflammatory immune conditioning of the tumor microenvironment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The combination of lefitolimod (administered subcutaneously or intratumorally) and ipilimumab was safe and well tolerated but demonstrated modest antitumor activity in patients with advanced cancers. ClinicalTrials.gov ID: NCT02668770<\/jats:p>\n                  <\/jats:sec>","DOI":"10.36401\/jipo-24-17","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:00:46Z","timestamp":1738868446000},"page":"89-98","source":"Crossref","is-referenced-by-count":3,"title":["Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial"],"prefix":"10.36401","volume":"8","author":[{"given":"Mirella","family":"Nardo","sequence":"first","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed A.","family":"Gouda","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J.","family":"Reilley","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amadeo B.","family":"Biter","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joann","family":"Lim","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stacie A.","family":"Bean","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ly M.","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya R.","family":"Bhosale","sequence":"additional","affiliation":[{"name":"2 Abdominal Imaging Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Casey R.","family":"Ager","sequence":"additional","affiliation":[{"name":"3 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coline A.","family":"Couillault","sequence":"additional","affiliation":[{"name":"3 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarina A.","family":"Piha-Paul","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqing","family":"Fu","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolia M.","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy A.","family":"Yap","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Rodon","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivek","family":"Subbiah","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel D.","family":"Karp","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Curran","sequence":"additional","affiliation":[{"name":"3 Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[{"name":"1 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22027","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"2025020700004016100_i2590-017X-8-2-89-b01","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2025020700004016100_i2590-017X-8-2-89-b02","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"2025020700004016100_i2590-017X-8-2-89-b03","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"2025020700004016100_i2590-017X-8-2-89-b04","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1200\/JCO.2010.28.9793","article-title":"In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I\/II study","volume":"28","author":"Brody","year":"2010","journal-title":"J Clin Oncol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b05","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.4049\/jimmunol.176.4.2635","article-title":"Tolerance induction by transcutaneous immunization through ultraviolet-irradiated skin is transferable through CD4+CD25+ T regulatory cells and is dependent on host-derived IL-10","volume":"176","author":"Ghoreishi","year":"2006","journal-title":"J Immunol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b06","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.4049\/jimmunol.179.5.2860","article-title":"Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine","volume":"179","author":"Webster","year":"2007","journal-title":"J Immunol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b07","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.4049\/jimmunol.0900974","article-title":"TLR3-stimulated dendritic cells up-regulate B7-H1 expression and influence the magnitude of CD8 T cell responses to tumor vaccination","volume":"183","author":"Pulko","year":"2009","journal-title":"J Immunol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b08","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1172\/JCI31414","article-title":"Development of TLR9 agonists for cancer therapy","volume":"117","author":"Krieg","year":"2007","journal-title":"J Clin Invest"},{"key":"2025020700004016100_i2590-017X-8-2-89-b09","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ejca.2014.11.002","article-title":"Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours","volume":"51","author":"Weihrauch","year":"2015","journal-title":"Eur J Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1089\/nat.2015.0533","article-title":"Design and structural requirements of the potent and safe TLR-9 agonistic immunomodulator MGN1703","volume":"25","author":"Schmidt","year":"2015","journal-title":"Nucleic Acid Ther"},{"key":"2025020700004016100_i2590-017X-8-2-89-b11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/s40425-019-0811-x","article-title":"TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma","volume":"7","author":"Reilley","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b12","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000940","article-title":"In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy","volume":"8","author":"Cheng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b13","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1158\/2159-8290.CD-21-0425","article-title":"Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma","volume":"11","author":"Ribas","year":"2021","journal-title":"Cancer Discov"},{"key":"2025020700004016100_i2590-017X-8-2-89-b14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002876","article-title":"Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer","volume":"9","author":"Carbone","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b15","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1158\/0008-5472.CAN-18-0729","article-title":"Inhaled TLR9 agonist renders lung tumors permissive to PD-1 blockade by promoting optimal CD4(+) and CD8(+) T-cell tnterplay","volume":"78","author":"Gallotta","year":"2018","journal-title":"Cancer Res"},{"key":"2025020700004016100_i2590-017X-8-2-89-b16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.7150\/thno.44417","article-title":"Hepatoma cell-intrinsic TLR9 activation induces immune escape through PD-L1 upregulation in hepatocellular carcinoma","volume":"10","author":"Zhou","year":"2020","journal-title":"Theranostics"},{"key":"2025020700004016100_i2590-017X-8-2-89-b17","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2025020700004016100_i2590-017X-8-2-89-b18","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-20-4118","article-title":"A phase I dose-escalation study to evaluate the safety and tolerability of evofosfamide in combination with ipilimumab in advanced solid malignancies","volume":"27","author":"Hegde","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025020700004016100_i2590-017X-8-2-89-b19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.4161\/onci.19731","article-title":"Effect of CpG ODN on monocytic myeloid derived suppressor cells","volume":"1","author":"Shirota","year":"2012","journal-title":"Oncoimmunology"},{"key":"2025020700004016100_i2590-017X-8-2-89-b20","doi-asserted-by":"crossref","first-page":"120","DOI":"10.7150\/jca.28120","article-title":"Incidence of ipilimumab-related serious adverse events in patients with advanced cancer: a meta-analysis","volume":"10","author":"Guo","year":"2019","journal-title":"J Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b21","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.2147\/OTT.S247050","article-title":"Toll-like receptor 9 agonists in cancer","volume":"13","author":"Karapetyan","year":"2020","journal-title":"Onco Targets Ther"},{"key":"2025020700004016100_i2590-017X-8-2-89-b22","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/CJI.0b013e318174a4df","article-title":"Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma","volume":"31","author":"Hofmann","year":"2008","journal-title":"J Immunother"},{"key":"2025020700004016100_i2590-017X-8-2-89-b23","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.jaad.2009.12.052","article-title":"Phase I trial of a toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma","volume":"63","author":"Kim","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b24","doi-asserted-by":"crossref","first-page":"E58","DOI":"10.3816\/CGC.2009.n.025","article-title":"Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I\/II study","volume":"7","author":"Thompson","year":"2009","journal-title":"Clin Genitourin Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b25","article-title":"O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab","volume":"8","author":"Milhem","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b26","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1200\/JCO.2006.07.9129","article-title":"Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma","volume":"24","author":"Pashenkov","year":"2006","journal-title":"J Clin Oncol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/CJI.0b013e31825481fe","article-title":"Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma","volume":"35","author":"Tarhini","year":"2012","journal-title":"J Immunother"},{"key":"2025020700004016100_i2590-017X-8-2-89-b28","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1002\/cncr.24473","article-title":"Randomized phase 2\/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma","volume":"115","author":"Weber","year":"2009","journal-title":"Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b29","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1093\/annonc\/mdy326","article-title":"Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study","volume":"29","author":"Thomas","year":"2018","journal-title":"Ann Oncol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b30","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1007\/s00432-014-1682-7","article-title":"Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial","volume":"140","author":"Schmoll","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025020700004016100_i2590-017X-8-2-89-b31","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","article-title":"SD-101 in Combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study","volume":"8","author":"Ribas","year":"2018","journal-title":"Cancer Discov"},{"key":"2025020700004016100_i2590-017X-8-2-89-b32","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/bjc.2013.227","article-title":"Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours","volume":"108","author":"Millward","year":"2013","journal-title":"Br J Cancer"},{"key":"2025020700004016100_i2590-017X-8-2-89-b33","doi-asserted-by":"crossref","first-page":"v560","DOI":"10.1093\/annonc\/mdz255.061","article-title":"1373TiP - ILLUMINATE 301: a randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy","volume":"30","author":"Butler","year":"2019","journal-title":"Ann Oncol"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/89\/3484569\/10.36401_jipo-24-17.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/8\/2\/89\/3484569\/10.36401_jipo-24-17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:27Z","timestamp":1765475307000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/8\/2\/article-p89.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2,7]]},"published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-24-17","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}